Biota Announces Royalties from Inavir® and Relenza™ for Q4 and F2011

Biota Holdings Limited (ASX:BTA) announces that it has received written notifications from GlaxoSmithKline (GSK) regarding royalties for Relenza™ and from Daiichi Sankyo for Inavir®. Indicative royalties from Relenza™ were $1.8m during the three months ended 30 June 2011. F2011 actual royalties are $6.6m. Royalties from of Inavir® were AUD 160k during the three months ended 30 June 2011, on sales of JPY 390m.

Indicative royalties and sales advised by GSK by quarter for the full financial year, are summarised below:

Q1

Q2

Q3

Q4

Adjustment*

Total

        
      
      
        
          Indicative royalties $m
        
        
           
        
        
           
        
        
          2.1
        
        
           
        
        
           
        
        
          1.2
        
        
           
        
        
           
        
        
          1.0
        
        
           
        
        
           
        
        
          1.8
        
        
           
        
        
           
        
        
          0.5
        
        
           
        
        
           
        
        
          6.6
        
      
      
        
          Indicative sales $m
        
        
           
        
        
           
        
        
          29.6
        
        
           
        
        
           
        
        
          17.9
        
        
           
        
        
           
        
        
          14.1
        
        
           
        
        
           
        
        
          18.0
        
        
           
        
        
           
        
        
          -
        
        
           
        
        
           
        
        
          79.6
        
      
      
        
        
        
           
        
        
           
        
        
        
        
           
        
        
           
        
        
        
        
           
        
        
           
        
        
        
        
           
        
        
           
        
        
        
        
           
        
        
           
        
        
        
        
           
        
        
           
        
        
        
      
    
    

* Adjusts indicative royalties reported during the year to actual and includes exchange rate corrections where appropriate.

Royalties and sales advised by Daiichi Sankyo since launch in October 2010, by quarter are summarised below:

Q2

Q3

Q4

Total

        
      
      
        
          Indicative royalties AUDm
        
        
           
        
        
           
        
        
          1.16
        
        
           
        
        
           
        
        
          1.60
        
        
           
        
        
           
        
        
          0.16
        
        
           
        
        
           
        
        
          2.92
        
      
      
        
          Indicative sales JPYbn
        
        
           
        
        
           
        
        
          2.8
        
        
           
        
        
           
        
        
          3.9
        
        
           
        
        
           
        
        
          0.4
        
        
           
        
        
           
        
        
          7.1
        
      
      
        
        
        
           
        
        
           
        
        
        
        
           
        
        
           
        
        
        
        
           
        
        
           
        
        
        
        
           
        
        
           
        
        
        
      
    
    

Biota will report actual royalties from Inavir® of AUD 2.92m for the year to 30 June 2011.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza™. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product lnavir®, is approved for marketing in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.

Inavir® is registered to Daiichi Sankyo.